Goldman Sachs: MSCI China Goldman Sachs maintains its bullish stance on Chinese stocks. Goldman Sachs’ latest research report pricts that the MSCI China Index and the CSI 300 Index will rise by about 20% by the end of 2025. Bas on the considerable riskreturn ratio, it is recommend to continue to increase holdings of Ashares and offshore Chinese stocks.
Goldman Sachs expects that as tariffs and policies become clearer, market sentiment and liquidity
environment may begin to improve at the end gambia email list 100000 contact leads of the first quarter. It recommends buying stocks that
benefit from government consumption, emerging market exporters that can benefit from the
depreciation of the RMB, and select technology and infrastructure companies; it also maintains an overweight rating on online retail, mia and healthcare stocks, while raising the rating of consumer services stocks to “overweight.”
10. UBTECH’s core executives ruce their holdings? Official response: Not true! No shares have been sold since listing
Recently, the market mistakenly report that UBTECH’s core management ruc its holdings after
promising a sales ban, sparking discussion. Relevant the person transporting the drugs person in charge of UBTECH also respond that
the company’s core executives Zhou Jian, Xiong Youjun and Wang Lin have never sold any of the company’s shares they directly hold since the listing. According to the nosale commitment, the three will not sell any shares in the next year.
The company’s core management has always maintain confidence in the company’s development
Xiong Youjun and Wang Lin both join UBTECH when it was first found in 2012, and became members
of the core management team with Zhou trust review Jian in the same year.
11. Leapmotor releas its earnings forecast, announcing that its net profit would turn positive in the
fourth quarter of 2024, achieving its singlequarter profit target one year ahead of schule. This marks that Leapmotor has become the second profitable new force Goldman Sachs: MSCI China.